Pharmacokinetics of Intrapartum Benzylpenicillin: Insights Into Candidate Regimens to Prevent Early Onset Neonatal Group B Streptococcus Disease
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.70072 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Bonniface Obura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Penicillin G, Streptococcal Infections, Anti-Bacterial Agents, Streptococcus agalactiae. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Early onset neonatal Group B Streptococcus (GBS) infection accounts for significant global morbidity and mortality. Intrapartum prophylaxis with benzylpenicillin is advised for women at high risk of having a baby affected by early onset GBS disease. Pregnancy‐related physiological changes can alter pharmacokinetics. To estimate the intrapartum pharmacokinetics of penicillin, women ( n = 12) at risk of GBS disease were enrolled. A fixed regimen of intravenous benzylpenicillin 3 g at onset of labor and 1.5 g every 4 h until delivery was used. Benzylpenicillin concentrations in plasma and umbilical cord were quantified. A nonparametric population pharmacokinetic model was fitted to the data and regimens that optimized drug exposure ( f C min > MIC for 100% of the dosing interval) were determined using Monte Carlo simulation. Benzylpenicillin pharmacokinetics were well described using a two‐compartment model with a linked umbilical cord compartment. The mean volume of the central compartment and first‐order clearance were 16.55 L and 41.24 L/h, respectively. Simulations showed that a lower regimen of benzylpenicillin 2.4 g followed by 1.2 g every 4 h resulted in adequate drug exposure—with plasma f C min > 0.125 mg/L for 100% of the dosing interval in > 90% of the simulated population. Simulations of a continuous infusion of benzylpenicillin resulted in higher target attainment rates when compared to intermittent dosing. Alternative intrapartum regimens of penicillin that are efficacious but require less total daily drug amounts appear feasible. Further research evaluating alternative regimens on clinical outcomes is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
- Department of Women's and Children's Health, University of Liverpool, Liverpool, UK.
- Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
- Fetal Medicine Unit, Liverpool Women's Hospital, Liverpool, UK.
- Harris-Wellbeing Research Centre, University of Liverpool, Liverpool, UK.
ORCID-Profile: Bonniface Obura, Catriona Waitt, Shampa Das, William Hope
Förderung
- Wellcome Trust
Zitieren
APA
Obura, B., Unsworth, J., Jimenez-Valverde, A., Waitt, C., Das, S., Hope, W., & Navaratnam, K. (2025). Pharmacokinetics of Intrapartum Benzylpenicillin: Insights Into Candidate Regimens to Prevent Early Onset Neonatal Group B Streptococcus Disease. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70072
Vancouver
Obura B, Unsworth J, Jimenez-Valverde A, Waitt C, Das S, Hope W, et al. Pharmacokinetics of Intrapartum Benzylpenicillin: Insights Into Candidate Regimens to Prevent Early Onset Neonatal Group B Streptococcus Disease. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70072
BibTeX
@article{Obura2025,
author = {Obura, Bonniface and Unsworth, Jennifer and Jimenez-Valverde, Ana and Waitt, Catriona and Das, Shampa and Hope, William and Navaratnam, Kate},
title = {Pharmacokinetics of Intrapartum Benzylpenicillin: Insights Into Candidate Regimens to Prevent Early Onset Neonatal Group B Streptococcus Disease},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.70072}
}
EUVIMED